More Biosimilars Of Herceptin And Remicade Get EMA Yes

 
• By Ian Schofield

The EMA’s CHMP has adopted positive opinions on two more biosimilar products: trastuzumab and infliximab. Sixteen biosimilars remain under review at the agency.

Recommendation
The CHMP has recommended EU approval of two more biosimilars.

More from Product Reviews

More from Pink Sheet